In autoimmune diseases, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), MS, and MS animal models (e.g., EAE), targeted inhibition of BTK and PI3K significantly affects the production of cytokines and autoantibodies, which effectively inhibits CNS inflammation and disease progression [6, 7]. The gene discussed is BTK; the disease is autoimmune disease.